Expression of the oxytocin receptor (OR) gene in vivo is known to be regulated by estradiol (E 2 ). We have cloned and sequenced 4 kilobases (kb) of 5Ј-flanking DNA of the rat OR gene and identified an internal segment of 1260 nucleotides that was absent in an initial publication of this promoter and an additional 2 kb of upstream sequence. This novel internal region is located between two large tg nucleotide repeats. PCR amplification using genomic DNA verified that this sequence is present in the rat genome. To explain transcriptional effects of E 2 , a palindromic estrogen response element (ERE) that is active in estrogen receptor binding was identified within this new sequence, approximately 4 kb 5Ј of the translational start site. The ability of E 2 to enhance transcription of this promoter was tested in transfection experiments in MCF7 cells. E 2 only weakly induced transcription of a truncated construct. Mutational analysis of the ERE in the context of a basal promoter indicated that it functions as an enhancer, and that mutation of two bases eliminates this activity. Further support of the efficacy of this response was shown in mobility gel shift assays in which the OR ERE bound estrogen receptor present in uterine extracts. Receptor binding studies using 125 I-ornithine vasotocin in MCF7 cells revealed that E 2 dramatically up-regulated endogenous ORs. Western blot analysis confirmed this increase in OR protein with E 2 treatment of MCF7 cells. These studies have identified a novel region of the rat OR promoter containing an upstream palindromic ERE that imparts E 2 inducibility of OR gene transcription. (Endocrinology 138: [1151][1152][1153][1154][1155][1156][1157][1158] 1997) T HE NEUROPEPTIDE oxytocin (OT) functions in important roles in both the periphery, as a neurohypophyseal hormone involved in lactation and parturition (1), and in the central nervous system, as a neurotransmitter involved in sex behavior and maternal aggression (2-6). Radioligand binding studies in rat brain have localized oxytocin receptors (ORs) to several regions, including the hippocampus (7, 8), paraventricular nucleus (9), and ventromedial hypothalamus (VMH) (10 -12). Further, in situ hybridization studies have localized an abundance of OR messenger RNA (mRNA) in the VMH (13). Both OR binding and mRNA studies have demonstrated that receptor expression is sensitive to gonadal steroids. Specifically, estrogen has been shown to increase the number of OR-binding sites and the mRNA level in the myometrium of the uterus (14, 15) and in the VMH of male and female brains (11-13, 16 -20). In females, the localization and density of OR mRNA in the VMH vary during the estrous cycle, particularly on the afternoon of proestrus when estrogen levels are maximal (21). Both the rat and human OR genes have been cloned and their 5Ј-flanking regions analyzed for regulatory elements (22-24). To date, no palindromic estrogen response elements (ERE) have been reported in the OR promoter; however, the presence of several half-EREs has been noted (22, 24). Transcriptional enhancement or protein binding capabilities of these half-elements have not been shown.
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T HE NEUROPEPTIDE oxytocin (OT) functions in im-
portant roles in both the periphery, as a neurohypophyseal hormone involved in lactation and parturition (1) , and in the central nervous system, as a neurotransmitter involved in sex behavior and maternal aggression (2) (3) (4) (5) (6) . Radioligand binding studies in rat brain have localized oxytocin receptors (ORs) to several regions, including the hippocampus (7, 8) , paraventricular nucleus (9) , and ventromedial hypothalamus (VMH) (10 -12) . Further, in situ hybridization studies have localized an abundance of OR messenger RNA (mRNA) in the VMH (13) . Both OR binding and mRNA studies have demonstrated that receptor expression is sensitive to gonadal steroids. Specifically, estrogen has been shown to increase the number of OR-binding sites and the mRNA level in the myometrium of the uterus (14, 15) and in the VMH of male and female brains (11-13, 16 -20) . In females, the localization and density of OR mRNA in the VMH vary during the estrous cycle, particularly on the afternoon of proestrus when estrogen levels are maximal (21) . Both the rat and human OR genes have been cloned and their 5Ј-flanking regions analyzed for regulatory elements (22) (23) (24) . To date, no palindromic estrogen response elements (ERE) have been reported in the OR promoter; however, the presence of several half-EREs has been noted (22, 24) . Transcriptional enhancement or protein binding capabilities of these half-elements have not been shown.
To determine how estrogen might influence transcription of the OR gene, we isolated and sequenced 4.5 kilobases (kb) of upstream sequence of a rat genomic clone. In doing so, we discovered a discrepancy in nucleic acid content and length between our clone and that which was previously reported (22) . This novel promoter sequence was then analyzed for regulatory elements and used in transfection assays to determine OR gene regulation by estrogen.
Materials and Methods

Screening and sequencing procedures
A phage GT10 rat genomic testes library was screened using oligonucleotides based on human OR sequence. Positive clones were digested with EcoRI and analyzed by Southern blotting. Membranes were probed with the same 32 P-labeled oligonucleotides used for screening. Positive fragments were then isolated, purified, and subcloned into pGEM7 (Promega). Sequencing was performed according to the Sequenase (U.S. Biochemical Corp., Cleveland, OH) protocol, using primers corresponding to flanking vector sequences and internal rat DNA sequences.
Verification of novel sequence in rat genome
As the genomic clone examined contained an additional sequence internal to that reported by Rozen et al. (22) , oligonucleotides were synthesized by PCR to verify the presence of our novel sequence in rat genomic DNA. Genomic DNA isolated from brain tissue in two rat strains (Long-Evans and Sprague-Dawley) was used for amplification. The sense oligonucleotide was located within the novel sequence (nucleotide 3396 -3416, 5Ј-ACATACGTGGTGCTGCAGCC-3Ј), whereas the antisense oligonucleotide was located within a previously reported sequence (nucleotide 4304 -4324, 5Ј-AAAGT-GGTTCATCGCAAGCCT-3Ј). The control reaction contained oligonucleotides synthesized from the coding region sequence (sense, oligonucleotides 4530 -4550; antisense, oligonucleotides 5900 -5920). The PCR reaction was carried out under standard conditions for Perkin-Elmer thermocycling: 1.5 mm MgCl 2 , 1 ϫ PCR buffer, 0.5 m oligonucleotide DNA, 1 g template DNA, and 0.25 mm nucleotides in a 100-l reaction for 35 cycles at temperatures of 95 C for 2.5 min, 57 C for 2.0 min, and 72 C for 1.5 min. PCR products were run on a 1% agarose gel for size determination. Further PCR amplification included using sense and antisense primers based on a previously reported sequence that was amplified across the internal region of the novel sequence.
Reporter gene constructs
Three reporter constructs were designed for use in transfection experiments (see Fig. 3 ). Portions of the OR promoter were subcloned into the luciferase plasmid pGL2B (Promega, Madison, WI). As shown in Fig. 3 , clone ORfp contained the full-length promoter, 4.5 kb upstream of the ATG translation start site. DNA clone ORp ϩ was a truncated form of the promoter, with an internal deletion of 3480 bp, bringing the upstream palindromic ERE into closer proximity to the transcription start site, previously reported by Rozen et al. (22) . Clone ORp Ϫ was the same clone as ORp ϩ , except the upstream region containing the ERE was removed by restriction enzyme digestion (NdeI).
Promoter constructs containing wild-type or mutant forms of the OR ERE were made using PCR amplification from the original OR clone in pGEM7 with oligonucleotides complementary to bases 556 -582 (antisense) and the T7 promoter/primer (Promega; sense). The antisense oligonucleotides were synthesized with a KpnI restriction enzyme site at the 3Ј-end (5Ј-AGGGCTAGCTGGGTCATCTGGAC-CAA-3Ј, wild type, ERE ϩ ) in addition, the mutant construct had two bases within the ERE mutated (5Ј-AGGGCTAGCTGGATCATCTG-GACAAA-3Ј, mutant, ERE Ϫ ). Both mutant and normal PCR products were restriction enzyme digested with KpnI and NheI (Promega), gel purified, subcloned into the enhancer site of the luciferase simian virus 40 promoter plasmid pGL3 (Promega), and used in transfection experiments as described below.
Transfection experiments
Transfection was performed by introduction of 3 g plasmid DNA/well into six-well plates containing MCF7 cells at 80% confluency using the lipid transfection agent, DOTAP (Boehringer Mannheim, Indianapolis, IN). Cells were treated with steroid hormone for 8 h and harvested after 15-min incubation in lysis buffer (Promega), unless otherwise specified. Cell extracts were used in luciferase assays according to the Promega luciferase assay protocol. The native pGL2 plasmid was used as a negative control for these experiments, such that each well's luciferase activity was subtracted by the negative control's luciferase activity for each experiment. For experiments involving the ERE as an enhancer in the pGL3 plasmid, the negative control was the native pGL3 plasmid. Results were normalized by cotransfection of ␤-galactosidase DNA, such that for each well the resulting luciferase light units were divided by the ␤-galactosidase activity for that well.
OR binding
Binding was performed on whole cell extracts from treated MCF7 cells. Cells were distributed into the desired number of flasks, with equal numbers of cells per flask. Flasks were randomly assigned to treatment groups and were treated at 90 -95% confluence for 24 h. Cells were harvested (2.5-3 ϫ 10 6 cells/flask) by trypsinization, pelleted by centrifugation, resuspended in PBS for washing, repelleted by centrifugation, and resuspended in a final volume of 3 ml PBS. Cells were frozen at Ϫ80 C until assay was performed.
Binding was performed using a cell harvester apparatus. GF-C membranes (Whatman, Clifton, NJ) were used for attachment of cells on harvester. Membranes were soaked in PBSBT (0.1% BSA, 0.02% tyrosine, and 0.1% MgCl 2 in PBS) plus 6 mg/ml BSA and 1 m OT at room temperature for 30 min. Binding reactions consisted of triplicate samples for specific and nonspecific conditions for each cell treatment. Each reaction contained approximately 2.5 ϫ 10 5 cells, 0.03 nm [ 125 I]ornithine vasotocin (OTA) (New England Nuclear, Boston, MA), and PBSBT buffer to a volume of 500 l. Nonspecific samples also contained 1 m unlabeled OT. Reactions were incubated for 15 min at 37 C before loading onto the harvester. Before loading cells, membranes were first rinsed with 250 ml of 0.2% polyethyleneimine. After cells were loaded onto membranes, incubation tubes and membranes were rinsed four times with 3 ml 50 mm Tris, pH 7.5. Membranes were then counted on a ␥-counter for quantitation of bound [
125 I]OTA. Averages of triplicates for nonspecific binding values were subtracted from averages of specific binding values for each treatment to determine specific binding.
Western blot analysis
MCF7 cells were treated with vehicle (ethanol) or 10 nm estradiol (E 2 ) for 24 h, then harvested by trypsinization and resuspended in 10 mm Tris-HCl (pH 7.4), 100 mm NaCl, and 1 mm dithiothreitol containing aprotinin (10 g/ml), leupeptin (10 g/ml), and pepstatin (1 m; homogenization buffer). Cells were homogenized and centrifuged for 5 min at 700 ϫ g, and the supernatant was removed and centrifuged at 100,000 ϫ g for 30 min. Membrane pellets were resuspended in 1 ml homogenization buffer, and the protein concentration was determined by Bradford analysis. Membrane proteins (10 g/lane) were separated by SDS-PAGE on a 10% Laemmli minigel and electrotransferred to nitrocellulose in a semidry transfer apparatus (Bio-Rad Laboratories, Richmond, CA) for 2 h at 15 V (constant voltage) with 25 mm Tris (pH 8.3), 192 mm glycine, 20% methanol, and 0.004% SDS as the transfer buffer. Unbound sites were blocked overnight at 4 C in 10 mm Tris and 0.15 m NaCl (pH 7.4; TBS) containing 5% (wt/vol) skim milk powder. Blots were washed three times for 10 min each time with TBS containing 0.05% Tween-20 (TBST) and incubated for 1 h with a 1:10,000 dilution of anti-OR antibody (25) in TBST. Blots were then washed three times for 10 min each time with TBST and incubated with horseradish-linked goat antirabbit antibody (1:20,000) in TBST for 1 h. Blots were again washed three times with TBST as described above, and immunoreactive bands were visualized using the Amersham ECL immunoblotting detection system (Amersham Corp., Arlington Heights, IL).
Mobility gel shift
The oligonucleotides synthesized were: the ERE of the vitellogenin promoter as a positive control (5Ј-GATCCAGGTCACTGTGACCTG-3Ј), the ERE for the OR (5Ј-CCTTGGTCCAGATGACCCAGC-3Ј), and a scrambled form of the OR ERE as a negative control (5Ј-CACTCGA-CATCAGCGTGTCGC-3Ј). Cytosolic extracts of parturient uterine tissue were prepared as reported previously (26) . Aliquots of extracts were incubated with 250 ng poly(dI-dC) in 20 l buffer [10 mm Tris-HCl (pH 7.5), 1 mm dithiothreitol, 100 mm KCl, 10% glycerol, and 3 g/l BSA] plus 32 P 5Ј-end-labeled oligonucleotides (20,000 cpm) for 15 min at room temperature (27) . Complexes were resolved by electrophoresis at 4 C on a 5% nondenaturing acrylamide gel equilibrated in 0.5 ϫ TBE (5 mm Tris and 0.5 mm EDTA). For supershift assays, 1 l of antiestrogen receptor (anti-ER) antibody (SRA1000, Stressgen, Vancouver, British, Columbia) was preincubated with cell extract overnight at 37 C before adding labeled oligonucleotides.
Results
Identification of novel sequence
During sequencing to obtain additional 5Ј-promoter sequence for transfection studies, important differences were noted between our OR clone and that previously described (22) . Primers designed for sequencing based on sequence from Rosen et al. (22) as well as those directed from previously unknown internal sequence toward published sequence in both 5Ј-and 3Ј-directions produced sequence in the 3Ј-direction that was not in the previous report. Continued sequencing revealed a third tg repeat and a 1.26-kb novel internal segment (nucleotides 3010 -4232 in Fig. 1 ).
Verification of sequence in rat genome
To confirm the presence of our clone in the rat genome, we performed PCR using primers corresponding to the newly identified sequence as well as to that specified in the original publication (22) . All PCR experiments indicated that the novel sequence was present in the rat genome, as evidenced by amplification of the predicted products based on our sequence data. A forward primer based on the novel internal sequence and a reverse primer based on the original published sequence were used to amplify a product 948 bp in length using genomic DNA from both Sprague-Dawley and Long-Evans rat strains (Fig. 2, A and  B) . DNA from two rat strains were used to verify that the discrepancy in sequence data was not due to a difference in OR genes between rat strains. A control PCR reaction was used to amplify coding region product of known length (Fig. 2C) . Further PCR reactions were performed to determine whether both this novel gene and the originally reported gene were present in the genome, suggesting the presence of two rat OR genes. None of these reactions yielded PCR products consistent with the previously reported sequence. The length of novel sequence is 1.26 kb and lies between the first two large tg repeats found in the 5Ј-flanking region of this genomic clone (Fig. 1) .
Novel internal and distal sequence of the rat OR promoter
In addition to the novel internal sequence described above, we also included an additional 2 kb of sequence 5Ј of the that previously reported (Fig. 2) . This distal sequence contains several potential transcription factorbinding sites, including several activating protein-1 (AP-1), AP-2, AP-3, and AP-4 sites and a half-serum response element site. Included in the novel internal sequence was a cAMP response element (CRE). A palindromic ERE, differing by 1 base from the consensus, was found 4 kb 5Ј of the translation start site. No typical CCAAT box was found in the novel sequence; however, a TATA-like motif was localized to a region approximately 100 bp from the transcription start site identified previously by Rozen et al. (22) using rapid amplification of 3Ј-cDNA ends cloning. Other putative elements of interest in the novel sequence include several half-glucocorticoid response elements and retinoic acid response elements.
Effects of estrogen on reporter gene constructs
Several different reporter gene constructs were created for use in transfection experiments to assess the effects of E 2 on OR promoter activity (Fig. 3) . Our initial experiments used the full-length construct (ORfp), and the two truncated constructs (ORp ϩ and ORp Ϫ ), which enabled us to examine the potential activity of the palindromic ERE located 4 kb upstream. Basal transcription was consistently enhanced in the full-length construct. In a typical experiment, when corrected for transfection efficiency, basal luciferase activity for the full-length construct in MCF7 cells was 2000 vs. 250 light units for the luciferase plasmid alone. Little induction in response to E 2 treatment was evident in the full-length (ORfp) construct. In contrast, exposure to 10 nm E 2 promoted a small, but consistent, 1.5-fold induction over vehicle levels of the ORp ϩ construct in MCF7 cells. This response was absent in the ORp Ϫ construct in which the upstream EREcontaining segment had been removed (Fig. 4) . Transfection assays using increasing concentrations of E 2 (from 10 -200 nm) showed no further effect on transcription (data not shown). As these truncated constructs were determined to not contain the newly identified TATA-like motif, we tested the induction capability of the ERE by subcloning it as an enhancer into a basal simian virus 40 reporter construct (pGL3).
Transfection experiments using the OR ERE-pGL3 construct showed that when placed in the enhancer region upstream of a basal simian virus 40 promoter, this ERE increased transcription in the presence of E 2 in a concentration-dependent manner, which became maximal at 200 nm (Fig. 5) . Mutation of only 2 bases in this ERE completely eliminated its ability to act as an enhancer after E 2 treatment. (Fig. 6) . Levels of specific binding in vehicletreated cells were low (37.6 cpm/tube), indicating a low basal state of expression of the OR in these cells.
Receptor binding experiments
Western blot analysis
E 2 (10 nm) treatment of MCF7 cells also increased OR protein, as shown by an increase in a specific band of approximately 70 kDa recognized by OR antibody 3580 (25) (Fig. 7) . This band has a mol wt similar to that previously shown for the OR (28, 29) .
Mobility gel shift
To determine whether the palindromic ERE identified in the distal segment of this clone was functional in ER binding, we conducted mobility gel shifts using cell extracts from a parturient rat uterus. Results from this gel shift indicated that the OR ERE binds ER, and this binding can be eliminated by preincubation with an anti-ER antibody (Fig. 8) . The OR ERE (OR-ERE) showed a somewhat lower binding affinity for the ER than the vitellogenen ERE, but was much greater than the scrambled sequence negative control. The anti-ER antibody abolished protein binding to both the vit-ERE and the OR-ERE.
FIG. 2. Products from PCR amplification of Sprague-Dawley (A) and
Long-Evans (B and C) genomic DNA. Amplification was performed using primers complementary to nucleotides 3396 -3416 (sense) to 4324 -4344 (antisense) in novel sequence (A and B) and control reaction using primers complementary to nucleotides 4530 -4550 (sense) to 5900 -5920 (antisense) in the coding region (C).
Discussion
We have identified a novel segment of internal sequence in 5Ј-flanking DNA of a rat OR gene that was missing from that reported by Rozen et. al (22) . Additional upstream sequence for this putative promoter is also included in this report. These new segments of sequence contain several interesting response elements, including a palindromic ERE, cAMP response element, half-serum response element, and several AP-1, AP-2, AP-3, and AP-4 sites. PCR amplification verified the presence of this novel promoter sequence in the genome of both Sprague-Dawley and Long-Evans rat strains. The novel segment of sequence reported in this study is flanked by extensive tg repeats. It is possible that these tg repeats caused DNA folding, which may have resulted in a looping out and loss of this segment during bacterial transformation and replicating procedures employed in the original cloning procedure (22) . PCR amplification using primers that should have produced two different sized bands if both genes were present in the genome only yielded a band of the correct size based on our sequence and not the previously reported sequence. Further attempts to amplify bands of the size predicted by the former sequence were also unsuccessful. Thus, it appears that the previously reported promoter sequence is missing 1260 bases, a deletion that may have occurred during bacterial replication.
Transfection experiments in MCF7 cells using the OR 5Ј-flanking DNA, including the newly identified segments, demonstrated that this promoter exhibits both basal and inducible transcriptional activity. E 2 exposure produced a variable response in MCF7 cells, enhancing transcription of the truncated ERE-containing construct (ORp ϩ ) 1.5 times that of vehicle, whereas induction was absent in the same construct lacking the ERE (ORp Ϫ ). No induction of transcription by E 2 was noted when the full-length construct (ORfp) was tested, suggesting that proximity of the distal ERE to the basal transcriptional machinery may be essential for E 2 inducibility.
Although the in vitro reporter gene assays failed to show the expected large induction of transcription by E 2 , the receptor binding studies demonstrated that E 2 can increase the number of endogenous OR-binding sites in MCF7 cells. Measurement of specific binding in vehicle-and E 2 -treated cells 
using [
125 I]OTA revealed a dramatic increase (17-fold) in OR binding. These results were supported by an increase in OR protein with E 2 treatment of MCF7 cells, as shown by Western blot analysis. It has previously been shown that MCF7 cells endogenously express ORs, but only at levels that require extremely sensitive methods for detection (30 -33) . The increase in OTA-binding sites and protein induced by E 2 in these cells supports in vivo data suggesting that transcription of this gene can be regulated by E 2 . These data also argue that the small estrogenic induction of transcription of the OR reporter constructs we have seen cannot be attributed to the use of a heterologous cell line that does not express ORs or the factors necessary to induce transcription of the OR gene.
Mobility gel shift assays showed that the OR ERE does bind ER, and this shifted complex can be eliminated by an anti-ER antibody. This protein-binding activity was specific, as no binding was seen for a scrambled oligonucleotide composed of the same length and gc content. Because the truncated reporter constructs used did not contain the newly identified TATA-like motif, we assessed the enhancer activity of the upstream palindromic ERE in a basal promoter. Interestingly, in the context of a basal promoter, the OR ERE-induced transcription in an E 2 concentration-dependent manner, whereas a mutant form of this ERE was nonresponsive to E 2 . These results suggest that if this ERE is involved in E 2 -induced gene transcription, it may be necessary that it be brought into closer proximity to the basal transcriptional apparatus, perhaps through DNA folding.
Several other genes known to be strongly regulated by E 2 in vivo exhibit only weak E 2 inducibility when exposed to E 2 in vitro (27, 34) . These results suggest several hypotheses. First, the effect of E 2 in vivo may be indirect and may be mediated by activation of protein kinase C and/or protein kinase A pathways. Several studies have been reported that support this possibility (35) (36) (37) (38) . Alternatively, the effects of E 2 in vivo may not be mimicked in vitro due to a requirement for a specific DNA configuration not achievable in our plasmid constructs. We have noted evidence of secondary structure formation caused by the three large tg repeat segments in this promoter. It is conceivable that these tg repeats serve important roles in promoter function and may allow response elements that are more distal to the transcription start site to be brought into closer proximity. Evidence for Z-DNA structure folding associated with promoter activation has been suggested for other genes, including the rat cholesterol 7␣-hydroxylase gene (39) . Steroid hormones are known to influence the formation of secondary structure required for promoter activity. For example, the chromatin structure of the mouse mammary tumor virus is dependent not only on the presence of certain steroid hormones, but also on the cell type and receptor status of the recipient cell into which it is transfected (40 -42) . Based on these reports, it is possible that the OR gene may rely on an induced secondary structure formed by the three tg repeats to exhibit E 2 induction. Lastly, it is reasonable to suggest the existence of a second OR gene, which may be responsive to E 2 . The existence of two OR genes might also provide an explanation for discrepancies that have been reported between OR mRNA and protein localization in the brain. OR binding studies have shown that OR binding is elim- inated in the VMH when female or male rats are gonadectomized, whereas binding is not affected in the central nucleus of the amygdala (12, 43) . It is possible then that the gene we have isolated and studied here is that which is responsible for this amygdala expression and, therefore, does not require E 2 for its induction.
In summary, we have sequenced and analyzed the rat OR promoter, including a novel 1.26-kb segment that had been deleted from the original published rat OR sequence, in addition to 2 kb of promoter sequence 5Ј of that previously reported (22) . Sequence analyses revealed a palindromic ERE in addition to numerous potential response elements within this sequence. Reporter constructs of this promoter demonstrated only a small transcriptional response to E 2 . However, reporter constructs containing the OR ERE as an enhancer in the context of a basal promoter demonstrated an E 2 -concentration dependent induction. The palindromic ERE identified in the distal portion of the OR promoter showed ER-binding activity in gel shift assays. Receptor binding and Western blot assays showed that E 2 treatment of MCF7 cells increased endogenous OR levels. Further studies are required to fully characterize modes of transcriptional regulation of this gene and their potential roles in OR expression in the brain and periphery.
